277 related articles for article (PubMed ID: 15255086)
1. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
3. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
Matlock A; Allan N; Wills B; Kang C; Leikin JB
Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
[TBL] [Abstract][Full Text] [Related]
4. FDA boxed warnings: how to prescribe drugs safely.
O'Connor NR
Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
[TBL] [Abstract][Full Text] [Related]
5. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
6. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments.
Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832
[TBL] [Abstract][Full Text] [Related]
7. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
9. Sources of drug information: FDA-approved labeling and other official FDA sources.
Lindstrom JA
Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
[TBL] [Abstract][Full Text] [Related]
10. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
11. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
12. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.
Cluxton RJ; Li Z; Heaton PC; Weiss SR; Zuckerman IH; Moomaw CJ; Hsu VD; Rodriguez EM
Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):1-9. PubMed ID: 15546159
[TBL] [Abstract][Full Text] [Related]
13. Primary care physicians' use of FDA-approved prescription drug labels.
Sullivan HW; O'Donoghue AC; Aikin KJ
J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
[TBL] [Abstract][Full Text] [Related]
14. Literacy demands of product information intended to supplement television direct-to-consumer prescription drug advertisements.
Kaphingst KA; Rudd RE; DeJong W; Daltroy LH
Patient Educ Couns; 2004 Nov; 55(2):293-300. PubMed ID: 15530767
[TBL] [Abstract][Full Text] [Related]
15. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
Olfson M; Marcus SC; Druss BG
Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
[TBL] [Abstract][Full Text] [Related]
16. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs.
Wang LM; Wong M; Lightwood JM; Cheng CM
Ann Pharmacother; 2010 Jan; 44(1):28-34. PubMed ID: 20040698
[TBL] [Abstract][Full Text] [Related]
17. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
Willke RJ; Burke LB; Erickson P
Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
[TBL] [Abstract][Full Text] [Related]
18. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
[TBL] [Abstract][Full Text] [Related]
19. The Physicians' Desk Reference. Problems and possible improvements.
Cohen JS; Insel PA
Arch Intern Med; 1996 Jul; 156(13):1375-80. PubMed ID: 8678706
[TBL] [Abstract][Full Text] [Related]
20. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]